Literature DB >> 27239386

Delayed Emergency Analgesia for Patients With Dementia and Hip Fracture.

Gerard Markey1, Noel Reilly1, Paul Kelly2, Conor Kelly1.   

Abstract

Entities:  

Year:  2016        PMID: 27239386      PMCID: PMC4872182          DOI: 10.1177/2151458516642581

Source DB:  PubMed          Journal:  Geriatr Orthop Surg Rehabil        ISSN: 2151-4585


× No keyword cloud information.
Dementia is a risk factor for hip fracture and is associated with poorer rehabilitation outcome[1] and decreased survival.[2,3] There is evidence to suggest that pain in patients with dementia and hip fractures may be undertreated in prehospital,[4] emergency department[4] (ED), and postoperative[5] settings. We studied consecutive new patients with hip fracture who presented to an ED with a census of 55 322 attendances per year in a regional Orthopaedic Centre in Ireland between January 01, 2013, and March 31, 2014, identified using a registry for the Irish National Hip Fracture Database. Patients were considered to have dementia when the diagnosis was documented in their medical notes, either prior to or during the index admission. The outcome measure used was time in minutes from ED arrival to the first dose of analgesic. Time-to-event analysis of the primary outcome was by the Kaplan-Meier method, stratified by cognitive status. We identified 133 consecutive patients who presented to ED de novo over 15 months with hip fractures. Of these 38 (29%) had documented dementia. The median Mini-Mental State Examination score of patients with dementia was 17, interquartile range (IQR) 10 to 19. The median age of patients with known dementia was 84 (IQR 79-87). The interval between ED arrival and first dose of analgesia was significantly longer for patients with dementia than for the cognitively intact, p = .027 (log rank; Figure 1). Median time to analgesia for patients with dementia was 164 minutes versus 90 minutes for the cognitively intact.
Figure 1.

Time to first dose of analgesia by cognitive status.

Time to first dose of analgesia by cognitive status. These findings suggest that timely pain relief for patients with dementia and hip fracture is problematic. Many factors, including clinician awareness, difficulty in detecting pain and assessing response to pain relief in patients with dementia, the potential for undertriage, and delayed diagnosis of fractures, may be involved. Recent studies in other health-care jurisdictions (United Kingdom[4] and Australia[6]) also reported dementia as a barrier to analgesia for hip fractures in the ED. Taken together with these, our study suggests that more active assessment and management of pain are required in this increasingly prevalent and vulnerable condition.
  6 in total

1.  A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture.

Authors:  R S Morrison; A L Siu
Journal:  J Pain Symptom Manage       Date:  2000-04       Impact factor: 3.612

2.  Survival in end-stage dementia following acute illness.

Authors:  R S Morrison; A L Siu
Journal:  JAMA       Date:  2000-07-05       Impact factor: 56.272

3.  Cognitive status at admission: does it affect the rehabilitation outcome of elderly patients with hip fracture?

Authors:  R J Heruti; A Lusky; V Barell; A Ohry; A Adunsky
Journal:  Arch Phys Med Rehabil       Date:  1999-04       Impact factor: 3.966

4.  Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988-2007.

Authors:  Nicole L Baker; Michael N Cook; H Michael Arrighi; Roger Bullock
Journal:  Age Ageing       Date:  2010-11-18       Impact factor: 10.668

5.  Patterns of analgesia for fractured neck of femur in Australian emergency departments.

Authors:  Anna Holdgate; Shamus A Shepherd; Sue Huckson
Journal:  Emerg Med Australas       Date:  2009-12-14       Impact factor: 2.151

6.  A case-control study examining inconsistencies in pain management following fractured neck of femur: an inferior analgesia for the cognitively impaired.

Authors:  J H McDermott; D R Nichols; M E Lovell
Journal:  Emerg Med J       Date:  2013-10-17       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.